CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$0.82 USD
-0.03 (-2.98%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $0.82 0.00 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CARM 0.82 -0.03(-2.98%)
Will CARM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARM
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Other News for CARM
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly